Trial Profile
Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Learnings from a Double-Blind, Randomized, Placebo-Controlled, Sequential Group First-in-Human Study of the TRPV1 Antagonist, JNJ-38893777, in Healthy Men.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Oct 2015
Price :
$35
*
At a glance
- Drugs JNJ 38893777 (Primary)
- Indications Neuropathic pain; Pain
- Focus First in man; Pharmacodynamics; Pharmacokinetics
- Sponsors Janssen Research & Development
- 29 Oct 2015 New trial record